

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5612639
<b>Application Number:</b>	09436347
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6491
<b>Title of Invention:</b>	TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODY
<b>First Named Inventor/Applicant Name:</b>	CHRISTINE A. WHITE
<b>Customer Number:</b>	47553
<b>Filer:</b>	David Lynn Devernoe/April Henderson
<b>Filer Authorized By:</b>	David Lynn Devernoe
<b>Attorney Docket Number:</b>	27693-01201
<b>Receipt Date:</b>	30-JUN-2009
<b>Filing Date:</b>	09-NOV-1999
<b>Time Stamp:</b>	11:50:32
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	8383
Deposit Account	181260
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCe1201.pdf	44425 fa6baa71e11ed1418654c6e240c8fca70e a88e	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		Amend1201.pdf	805479 8c19a83a6218caef11a200005e5d1bd7810f 0a066	yes	18
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment After Final		1	1	
	Applicant Arguments/Remarks Made in an Amendment		2	18	
Warnings:					
Information:					
3	Oath or Declaration filed	Dec1201.pdf	500029 cf724b1e3136a87818fe10fdaf594791050e ba50	no	11
Warnings:					
Information:					
4		IDS_1449_1201.pdf	116609 4ba6d2965808b67312ae71725cae9b107174e a9c17	yes	4
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement (IDS) Filed (SB/08)		1	2	
	Information Disclosure Statement (IDS) Filed (SB/08)		3	4	
Warnings:					
Information:					
5	NPL Documents	1ref1201.pdf	115562 7215c8cae5d6c52abbc66d158b80ef5a08 681b	no	3
Warnings:					

Information:					
6	NPL Documents	2ref1201.pdf	22084	no	1
			df8bab6b121b5e9e0d115d1792bcb2c1071c600c		
Warnings:					
Information:					
7	NPL Documents	3ref1201.pdf	50003	no	1
			105180f469b69341d0ee876dbae8514e40c55f0		
Warnings:					
Information:					
8	NPL Documents	4ref1201.pdf	95935	no	3
			835e2af2f803d938b144d5d6c1e11eebba6c2		
Warnings:					
Information:					
9	NPL Documents	5ref1201.pdf	58828	no	2
			759990bb17180b520001b77d8f80b6c9c2e6d2		
Warnings:					
Information:					
10	NPL Documents	6ref1201.pdf	101212	no	3
			695c771ae422f6e95f46d6b821090b552ed1ff62e		
Warnings:					
Information:					
11	NPL Documents	7ref1201.pdf	111705	no	2
			e625f802f8cc0352b601099022ae6b5c7fae76eb9		
Warnings:					
Information:					
12	NPL Documents	8ref1201.pdf	531388	no	7
			910e5e5de2f5de32ef53c95a7e37a744e6414946af		
Warnings:					
Information:					
13	NPL Documents	9ref1201.pdf	114041	no	3
			d845cc852402554683be7b217cc7f748626090eac6		
Warnings:					
Information:					
14	NPL Documents	10ref1201.pdf	73997	no	3
			28c551ea26722c5c531386108b073d9111293148		
Warnings:					

<b>Information:</b>					
15	NPL Documents	11ref1201.pdf	477618 79f020ba09c310c6086c3c0a34a23730c c5e9	no	6
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	12ref1201.pdf	607340 60f11be99ef5682b5cf8041c168b5dedc3b b002	no	6
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	13ref1201.pdf	355219 e933164241bf65a7c7e02506a34c70715a0 d2224	no	5
<b>Warnings:</b>					
<b>Information:</b>					
18	Fee Worksheet (PTO-875)	fee-info.pdf	30628 70261487b2a5ee07c3216db215a5e090bf e053d	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			4212102		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					